Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 10/28 07:39:15 pm
142.9214 USD   -10.99%
04:26p NASDAQ 100 MOVE : Amgn, srcl
03:56pDJABBVIE : Sales of AbbVie's Humira Miss Expectations
03:36pDJU.S. HOT STOCKS : Hot Stocks to Watch
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
04:26p NASDAQ 100 MOVERS : Amgn, srcl
03:56pDJABBVIE : Sales of AbbVie's Humira Miss Expectations
03:36pDJU.S. HOT STOCKS : Hot Stocks to Watch
10/27DJAMGEN : Sees Profit Increase, Raises Guidance -- Update
10/27 AMGEN INC : Results of Operations and Financial Condition, Financial Statements ..
10/27 WEST PHARMACEUTICAL SERVICES : to Showcase Expertise in Injectable Drug Containm..
10/27 AMGEN : tops Street 3Q forecasts
10/27 AMGEN : tops Street 3rd-quarter profit and revenue forecasts
10/26 AMGEN : Ferguson Wellman Capital Management Inc buys $45,280,733 stake in Amgen
More news
Sector news : Bio Therapeutic Drugs
10:53a Drugmaker Sanofi hungry for deals after earnings beat
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:24p Biotechs Pounded While Market Sits In A Holding Pattern
10:42a Amgen sinks after company dashes expectations of pushing through price increa..
06:59a WALL STREET BREAKFAST : Traders Look To GDP Report
10/27 Amgen (AMGN) Q3 2016 Results - Earnings Call Transcript
10/27 Amgen Inc. 2016 Q3 - Results - Earnings Call Slides
Financials ($)
Sales 2016 22 770 M
EBIT 2016 10 966 M
Net income 2016 7 494 M
Debt 2016 2 009 M
Yield 2016 2,43%
P/E ratio 2016 16,19
P/E ratio 2017 14,98
EV / Sales 2016 5,37x
EV / Sales 2017 5,00x
Capitalization 120 164 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 188 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-1.08%120 164
GILEAD SCIENCES, INC.-25.06%100 070
ACTELION LTD3.22%15 535
More Results